Claims
- 1. A method of growing a transgenic plant comprising:
providing a transgenic plant or a seed or seedling thereof comprising a transgene, the transgene comprising a promoter and, operably linked to the promoter, a sequence that, when expressed, alters the level of a hormone and causes at least one phenotype in the transgenic plant or seed or seedling thereof that is abnormal compared with an otherwise identical plant or seed or seedling thereof that lacks the transgene; applying a composition that comprises a first compound that is metabolized by the seed or seedling to produce a second compound that substantially eliminates the abnormal phenotype to the transgenic plant or seed or seedling thereof; and growing the transgenic plant or seed or seedling thereof to produce a phenotypically normal transgenic plant.
- 2. The method of claim 1, wherein:
the hormone is a gibberellin; and the first compound is a GA compound.
- 3. The method of claim 2, wherein the sequence, when expressed, causes at least one phenotype selected from the group consisting of a shortened hypocotyl, shortened epicotyl, and both a shortened hypocotyl and shortened epicotyl.
- 4. The method claim 2, wherein the first compound is a gibberellin precursor or a gibberellin biosynthetic intermediate.
- 5. The method of claim 2, wherein the first compound is ent-kaurene, ent-kaurenoic acid, ent-7α-hydroxykaurenoic acid, steviol, GA12-aldehyde, GA12, GA15, GA24, GA9, GA53, GA44, GA19, GA20, GA5, or GA3-3-acetate.
- 6. The method of claim 2, wherein the first compound is GA9, GA15, GA19, GA24, GA44, GA53, GA5, or steviol.
- 7. The method of claim 1, wherein the sequence, when expressed, reduces expression of an enzyme in the pathway for biosynthesis of the hormone.
- 8. The method of claim 7, wherein the sequence is in an antisense orientation with respect to the promoter.
- 9. The method of claim 7, wherein the enzyme is copalyl diphosphate synthase, a 3β-hydroxylase, or a C-20 oxidase.
- 10. The method of claim 9, wherein the sequence comprises at least 15 contiguous nucleotides of, or that hybridizes under high stringency conditions to, SEQ ID NO:1, 2, 3, 4, 5, 6, 8, or complements thereof.
- 11. The method of claim 1, wherein the sequence encodes an enzyme that inactivates the hormone.
- 12. The method of claim 11, wherein:
the hormone is a gibberellin; and the sequence encodes a GA 2-oxidase.
- 13. The method of claim 12, wherein the sequence has at least 85% nucleotide sequence identity with SEQ ID NO:57, 58, 60, 62, 64, 66, 67, 68, 69, 70, or 71.
- 14. The method of claim 12, wherein the sequence encodes a GA 2-oxidase having at least 70% amino acid sequence identity with an Arabidopsis GA 2-oxidase 4, an Arabidopsis 2-oxidase 5, a soybean GA 2-oxidase 1, a soybean GA 2-oxidase 2, a cotton GA 2 oxidase-1, a cotton GA 2 oxidase-2, a cotton GA 2 oxidase-3, a maize GA 2-oxidase 1, or a maize 2-oxidase 2.
- 15. The method of claim 1, wherein the sequence encodes an enzyme that metabolizes a precursor of the hormone to produce a metabolite that is not a precursor of the hormone in the transgenic plant.
- 16. The method of claim 15, wherein:
the hormone is a gibberellin; and the enzyme is a phytoene synthase, a C-20 oxidase, or a 2β,3β-hydroxylase.
- 17. The method of claim 16, wherein the sequence has at least 85% nucleotide sequence identity with SEQ ID NO:75, 77, or 79.
- 18. The method of claim 16, wherein the sequence encodes an enzyme having at least 70% amino acid sequence identity with a tomato phytoene synthase, a pumpkin C-20 oxidase, or a pumpkin 2β,3β-hydroxylase.
- 19. The method of claim 1, wherein the promoter is preferentially expressed in developing seeds, during seed germination, or in young seedlings.
- 20. The method of claim 1, comprising applying the composition to soil or directly to the seed or seedling.
- 21. A method of growing a transgenic plant comprising:
providing a transgenic plant or a seed or seedling thereof comprising a transgene, the transgene comprising a promoter and, operably linked to the promoter, a sequence that, when expressed, alters the level of an enzyme in the gibberellin biosynthetic pathway and causes a phenotype in the transgenic plant or the seed or seedling thereof that is abnormal compared with an otherwise identical plant or seed or seedling thereof that lacks the transgene; applying a composition that comprises at least one GA compound to the transgenic plant or the seed or seedling thereof; and growing the transgenic plant or the seed or seedling thereof to produce a phenotypically normal transgenic plant.
- 22. The method of claim 21, wherein the enzyme is a copalyl diphosphate synthase, a 3β-hydroxylase, or a C-20 oxidase.
- 23. The method of claim 22, wherein the sequence comprises a member of the group consisting of:
a) at least 15 contiguous nucleotides of SEQ ID NO:1, 2, 3, 4, 5, 6, or 8; b) a sequence having at least 85% nucleotide sequence identity with SEQ ID NO:1, 2, 3, 4, 5, 6, or 8; and c) a sequence that encodes a polypeptide having at least 70% amino acid sequence identity with a polypeptide encoded by member of the group consisting of SEQ ID NO:1, 2, 3, 4, 5, 6, 8.
- 24. The method of claim 21, wherein the promoter is preferentially expressed in developing seeds, during seed germination, or in early seedlings.
- 25. The method of claim 21, wherein the GA compound is ent-kaurene, ent-kaurenoic acid, ent-7α-hydroxykaurenoic acid, steviol, GA12-aldehyde, GA12, GA15, GA24, GA9, GA53, GA44, GA19, GA20, GA5, GA4, GA7, GA3, or GA3-3-acetate.
- 26. The method of claim 21, wherein the GA compound is GA9, GA15, GA19, GA24, GA44, GA53, GA5, or steviol.
- 27. The method of claim 21, wherein the promoter is preferentially expressed in developing seeds, during seed germination, or in early seedlings.
- 28. A method of growing a transgenic plant comprising:
providing a transgenic plant or a seed or seedling thereof comprising a transgene, the transgene comprising a promoter and, operably linked to the promoter, a sequence that encodes an enzyme that inactivates an endogenous gibberellin, causing at least one phenotype in the transgenic plant or the seed or seedling thereof that is abnormal compared with an otherwise identical plant or seed or seedling thereof that lacks the transgene; applying a composition that comprises at least one GA compound that is metabolized by the seed or seedling to produce a product having gibberellin activity that is not inactivated by the enzyme to the transgenic plant or the seed or seedling thereof; and growing the transgenic plant or the seed or seedling thereof to produce a phenotypically normal transgenic plant.
- 29. The method of claim 28, wherein the enzyme is a GA 2-oxidase.
- 30. The method of claim 29, wherein the sequence has at least 85% nucleotide sequence identity with SEQ ID NO:57, 58, 60, 62, 64, 66, 67, 68, 69, 70, or 71.
- 31. The method of claim 30, wherein the sequence encodes a GA 2-oxidase having at least 70% amino acid identity with an Arabidopsis GA 2-oxidase 4, an Arabidopsis 2-oxidase 5, a soybean GA 2-oxidase 1, a soybean GA 2-oxidase 2, a cotton GA 2 oxidase-1, a cotton GA 2 oxidase-2, a cotton GA 2 oxidase-3, a maize GA 2-oxidase 1, or a maize 2-oxidase 2.
- 32. The method of claim 28, wherein the promoter is preferentially expressed in developing seeds, during seed germination, or in early seedlings.
- 33. The method of claim 28, wherein the GA compound is GA4, GA7, GA3, or GA3-3-acetate.
- 34. The method of claim 33, wherein the GA compound is GA3 or GA3-3-acetate.
- 35. A method of growing a transgenic plant comprising:
providing a transgenic plant or a seed or seedling thereof comprising a transgene, the transgene comprising a promoter and, operably linked to the promoter, a sequence that encodes an enzyme that metabolizes a gibberellin precursor to produce a metabolite that is not a gibberellin precursor, thereby reducing the level of a gibberellin and causing at least one phenotype in the transgenic plant or the seed or seedling thereof that is abnormal compared with an otherwise identical plant or seed or seedling thereof that lacks the transgene; applying a composition that comprises at least one GA compound that substantially eliminates the abnormal phenotype to the seed or seedling of the transgenic plant; and growing the transgenic plant or seed or seedling thereof to produce a phenotypically normal transgenic plant.
- 36. The method of claim 35, wherein the enzyme is a phytoene synthase, a C-20 oxidase, or a 2β,3β-hydroxylase.
- 37. The method of claim 35, wherein the enzyme is a tomato phytoene synthase, a pumpkin C-20 oxidase, or a pumpkin 2β,3β-hydroxylase.
- 38. The method claim 36, wherein:
the enzyme is a phytoene synthase; and the GA compound is ent-kaurene, ent-kaurenoic acid, ent-7α-hydroxykaurenoic acid, steviol, GA12-aldehyde, GA12, GA15, GA24, GA9, GA53, GA44, GA19, GA20, GA5, GA4, GA7, GA3, or GA3-3-acetate.
- 39. The method of claim 36, wherein:
the enzyme is a phytoene synthase; and the GA compound is GA9, GA15, GA19, GA24, GA44, GA53, GA5 or steviol.
- 40. The method claim 36, wherein:
the enzyme is a C-20 oxidase; and the GA compound is GA9, GA4, GA20, GA1, GA7, GA3, or GA3-3-acetate.
- 41. The method of claim 36, wherein:
the enzyme is a C-20 oxidase; and the GA compound is GA3 or GA3-3-acetate.
- 42. The method claim 36, wherein:
the enzyme is a 2β,3β-hydroxylase; and the GA compound is GA9, GA41, GA53, GA44, GA19, GA20, GA15, GA7, GA3, or GA3-3-acetate.
- 43. The method of claim 40, wherein the GA compound is GA3 or GA3-3-acetate.
- 44. The method of claim 35, wherein the promoter is preferentially expressed in developing seeds, during seed germination, or in early seedlings.
- 45. A nucleic acid segment comprising at least 12 contiguous nucleotides of a sequence selected from the group consisting of SEQ ID NO:1, 2, 3, 4, 5, 6, 8, 57, 58, 60, 62, 64, 66, 67, 68, 69, 70, 71, 75, 77, 79, and complements thereof, wherein the nucleic acid segment hybridizes specifically to the selected sequence under stringent hybridization conditions.
- 46. A nucleic acid construct comprising operably linked:
a promoter that causes expression of an operably linked nucleic acid segment in a plant cell; and a nucleic acid segment comprising at least 12 contiguous nucleotides of a sequence selected from the group consisting of SEQ ID NO:1, 2, 3, 4, 5, 6, 8, 57, 58, 60, 62, 64, 66, 67, 68, 69, 70, 71, 75, 77, 79, and complements thereof, wherein the nucleic acid segment hybridizes specifically to the selected sequence under stringent hybridization conditions.
- 47. The nucleic acid construct of claim 45, wherein:
the nucleic acid segment is SEQ ID NO:1, 2, 3, 4, 5, 6, or 8; and expression of the nucleic acid segment in the plant cell reduces a level of an endogenous gibberellin compared with an otherwise identical plant cell in which the nucleic acid segment is not expressed.
- 48. The nucleic acid segment of claim 47, wherein the nucleic acid segment is in antisense orientation with respect to the promoter.
- 49. A transgenic plant comprising a nucleic acid segment comprising at least 12 contiguous nucleotides of a sequence selected from the group consisting of SEQ ID NO:1, 2, 3, 4, 5, 6, 8, 57, 58, 60, 62, 64, 66, 67, 68, 69, 70, 71, 75, 77, 79, and complements thereof, wherein the nucleic acid segment hybridizes specifically to the selected sequence under stringent hybridization conditions.
- 50. The transgenic plant of claim 49, characterized by at least one phenotype selected from the group consisting of a shortened hypocotyl, shortened epicotyl, and both a shortened hypocotyl and shortened epicotyl compared with an otherwise identical plant that lacks the nucleic acid segment.
- 51. A nucleic acid segment comprising a sequence of at least 100 nucleotides having at least 85% nucleotide sequence identity with SEQ ID NO:1, 2, 3, 4, 5, 6, 8, 57, 58, 60, 62, 64, 66, 67, 68, 69, 70, 71, 75, 77, 79, or complements thereof.
- 52. The nucleic acid segment of claim 51, comprising a sequence of at least 100 nucleotides having at least 85% nucleotide sequence identity with SEQ ID NO:1, 2, 3, 4, or complements thereof, wherein the sequence encodes a polypeptide with copalyl diphosphate synthase activity.
- 53. The nucleic acid segment of claim 51, comprising a sequence of at least 100 nucleotides having at least 85% nucleotide sequence identity with SEQ ID NO:5, 6, or complements thereof, wherein the sequence encodes a polypeptide with 3β-hydroxylase activity.
- 54. The nucleic acid segment of claim 51, comprising a sequence of at least 100 nucleotides having at least 85% nucleotide sequence identity with SEQ ID NO:8, 77, or complements thereof, wherein the sequence encodes a polypeptide with C-20 oxidase activity.
- 55. The nucleic acid segment of claim 51, comprising a sequence of at least 100 nucleotides having at least 85% nucleotide sequence identity with SEQ ID NO: 57, 58, 60, 62, 64, 66, 67, 68, 69, 70, 71, or complements thereof, wherein the sequence encodes a polypeptide with GA 2-oxidase activity.
- 56. The nucleic acid segment of claim 51, comprising a sequence of at least 100 nucleotides having at least 85% nucleotide sequence identity with SEQ ID NO: 75 or the complement thereof, wherein the sequence encodes a polypeptide with phytoene synthase activity.
- 57. The nucleic acid segment of claim 51, comprising a sequence of at least 100 nucleotides having at least 85% nucleotide sequence identity with SEQ ID NO: 79 or the complement thereof, wherein the sequence encodes a polypeptide with 2β,3β-hydroxylase activity.
- 58. A transgenic plant comprising a nucleic acid segment; wherein the nucleic acid segment comprises a sequence of at least 100 nucleotides having at least 85% nucleotide sequence identity with SEQ ID NO:1, 2, 3, 4, 5, 6, 8, 57, 58, 60, 62, 64, 66, 67, 68, 69, 70, 71, 75, 77, 79, or complements thereof.
- 59. The transgenic plant of claim 58, characterized by at least one phenotype selected from the group consisting of a shortened hypocotyl, shortened epicotyl, and both a shortened hypocotyl and shortened epicotyl compared with an otherwise identical plant that lacks the nucleic acid segment.
- 60. A nucleic acid construct comprising a promoter that causes expression of an operably linked nucleic acid segment in a plant cell and, operably linked to the promoter, the nucleic acid segment comprising a sequence that encodes a polypeptide having a GA 2-oxidase activity, wherein expression of the nucleic acid segment in the plant cell results in inactivation of an endogenous gibberellin in the plant cell, thereby reducing levels of the endogenous gibberellin in the plant cell compared with an otherwise identical plant cell in which the nucleic acid segment is not expressed.
- 61. The nucleic acid construct of claim 60, wherein the sequence encodes a polypeptide having at least 70% amino acid sequence identity with a polypeptide encoded by SEQ ID NO:57, 58, 60, 62, 64, 66, 67, 68, 69, 70, 71, or the complements thereof.
- 62. The nucleic acid segment of claim 61, encoding a polypeptide having only silent or conservative substitutions to the polypeptide encoded by SEQ ID NO:57, 58, 60, 62, 64, 66, 67, 68, 69, 70, 71, or the complements thereof.
- 63. The nucleic acid segment of claim 61, encoding a polypeptide identical to the polypeptide encoded by SEQ ID NO:57, 58, 60, 62, 64, 66, 67, 68, 69, 70, 71, or the complements thereof.
- 64. A transgenic plant comprising a nucleic acid segment, wherein the nucleic acid segment comprises a promoter that causes expression of an operably linked nucleic acid segment in a plant cell and, operably linked to the promoter, the nucleic acid segment comprising a sequence that encodes a polypeptide having a GA 2-oxidase activity, wherein expression of the nucleic acid segment in the plant cell results in inactivation of an endogenous gibberellin in the plant cell, thereby reducing levels of the endogenous gibberellin in the plant cell compared with an otherwise identical plant cell in which the nucleic acid segment is not expressed.
- 65. The transgenic plant of claim 64, characterized by at least one phenotype selected from the group consisting of a shortened hypocotyl, shortened epicotyl, and both a shortened hypocotyl and shortened epicotyl compared with an otherwise identical plant that lacks the nucleic acid segment.
- 66. A nucleic acid construct comprising a promoter that causes expression of an operably linked nucleic acid segment in a plant cell and, operably linked to the promoter, a nucleic acid segment encoding a polypeptide having an activity selected from the group consisting of phytoene synthase activity, a C-20 oxidase activity, and a 2β,3β-hydroxylase activity, wherein expression of the nucleic acid segment in the plant cell results in metabolism of a gibberellin precursor in the plant cell to produce a metabolite that is not a gibberellin precursor in the plant cell, thereby reducing levels of the endogenous gibberellin in the plant cell compared with an otherwise identical plant cell in which the nucleic acid segment is not expressed.
- 67. The nucleic acid construct of claim 66, wherein the sequence encodes a polypeptide having at least 70% amino acid sequence identity with a polypeptide encoded by SEQ ID NO:75, 77, 79, or the complements thereof.
- 68. The nucleic acid segment of claim 66, encoding a polypeptide having only silent or conservative substitutions to the polypeptide encoded by SEQ ID NO: 75, 77, 79, or the complements thereof.
- 69. The nucleic acid segment of claim 66, encoding a polypeptide identical to the polypeptide encoded by SEQ ID NO:75, 77, 79, or the complements thereof.
- 70. A transgenic plant comprising a nucleic acid segment, wherein the nucleic acid segment comprises a promoter that causes expression of an operably linked nucleic acid segment in a plant cell and, operably linked to the promoter, a nucleic acid segment encoding a polypeptide having an activity selected from the group consisting of phytoene synthase activity, a C-20 oxidase activity, and a 2β,3β-hydroxylase activity, wherein expression of the nucleic acid segment in the plant cell results in metabolism of a gibberellin precursor in the plant cell to produce a metabolite that is not a gibberellin precursor in the plant cell, thereby reducing levels of the endogenous gibberellin in the plant cell compared with an otherwise identical plant cell in which the nucleic acid segment is not expressed.
- 71. The transgenic plant of claim 70, characterized by at least one phenotype selected from the group consisting of a shortened hypocotyl, shortened epicotyl, and both a shortened hypocotyl and shortened epicotyl compared with an otherwise identical plant that lacks the nucleic acid segment.
- 72. A promoter that is operable in a plant cell, the promoter comprising at least 15 contiguous nucleotides of SEQ ID NO:7.
- 73. The promoter of claim 72, comprising at least 100 contiguous nucleotides of SEQ ID NO:7.
- 74. The promoter of claim 73, that is preferentially expressed in seedlings.
- 75. A transgenic plant comprising a promoter, wherein the promoter comprises at least 15 contiguous nucleotides of SEQ ID NO:7.
- 76. A composition comprising:
one or more seeds of a plant that has a gibberellin-deficiency that results in at least one abnormal phenotype in the seed or in a seedling of the plant compared with a seed or seedling of an otherwise identical plant having wild-type levels of gibberellin; and a composition applied to a surface of the seed that comprises an amount of at least one GA compound that is effective to substantially eliminate the abnormal phenotype.
- 77. The composition of claim 76, wherein the GA compound is ent-kaurene, ent-kaurenoic acid, ent-7α-hydroxykaurenoic acid, steviol, GA12-aldehyde, GA12, GA15, GA24, GA9, GA53, GA44, GA19, GA20, or GA5.
- 78. The composition of claim 76, wherein the GA compound is GA9, GA15, GA19, GA24, GA44, GA53, GA5, or steviol.
- 79. The composition of claim 76, wherein the plant is a transgenic plant comprising a transgene comprising a promoter and, operably linked to the promoter, a sequence that, when expressed, reduces gibberellin levels in the seed or seedling.
CROSS REFERENCES TO RELATED APPLICATIONS
[0001] This Patent Application is related to U.S. Provisional Patent Application Nos. 60/096,111, filed Aug. 10, 1998 and 60/137,977, filed Jun. 7, 1999. Both of these priority documents are incorporated by reference in their entirely.